Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Trellus Health PLC ( (GB:TRLS) ) has shared an update.
Trellus Health PLC announced its unaudited interim results for the first half of 2025, highlighting significant operational and financial developments. The company achieved key milestones, including a partnership with Johnson & Johnson Health Care Systems and a renewed licensing agreement with Pfizer. Despite a decrease in net cash and an adjusted EBITDA loss of $3.5 million, Trellus Health reported increased revenue and reduced monthly cash burn. The company plans to explore fundraising options to extend its cash runway and support its strategic growth initiatives, which include expanding its clinical trial vertical and strengthening partnerships.
More about Trellus Health PLC
Trellus Health PLC is a healthcare company that provides innovative, value-based solutions for managing chronic conditions through its Trellus Elevate® digital platform. The company focuses on pharmaceutical patient support programs, clinical trial recruitment and retention services, and the U.S. health plan sector. Trellus Health’s approach integrates data analytics with resilience programs to empower patients, particularly those with chronic gastrointestinal conditions like Inflammatory Bowel Disease (IBD), to manage their health effectively.
Average Trading Volume: 984,391
Technical Sentiment Signal: Sell
Current Market Cap: £1.29M
For a thorough assessment of TRLS stock, go to TipRanks’ Stock Analysis page.